A chronic conflict in Middle East may start to harm India’s exports not simply to the region but in addition to different world markets, as disrupted provide chains ripple outward, commerce secretary Rajesh Agrawal mentioned on Saturday, He additionally urged the pharmaceutical trade to scale back dependence on imported uncooked supplies and construct extra resilient export and import linkages.Speaking on the sidelines of ‘Chintan Shivir – Scaling Up Pharma Exports’ in Hyderabad, Agrawal mentioned the government has already seen an impression on each imports and exports over the previous month due to the Middle East disaster, with power imports and regional commerce flows beneath strain.“Middle East is also an important market. Around 12-13 per cent of our exports go to the region. So, that will directly get impacted. And if it goes on for long, maybe our exports to other parts of the world will also get impacted as some of the value chains will rotate back. We are cognizant of it,” Agrawal informed reporters, as per information company PTI.He mentioned the precise impression of the conflict on India’s commerce would turn out to be clearer within the subsequent couple of weeks, however indicated that each exports and imports may see some decline.“And I assume, it will not only be a one-way traffic, in terms of export going down, but it will also be imports having some downfall,” he mentioned.Agrawal cautioned that even if the warfare ends quickly, the disruption may linger for months and even years, relying on the extent of harm to provide chains and infrastructure.“So, at this juncture, it will be very difficult to take a very long-term view on it,” he mentioned.He mentioned the Centre is making an attempt to make sure that provide chains face the minimal attainable disruption, whereas acknowledging that some commerce numbers may soften within the close to time period.
Pharma sector already feeling provide strain
The commerce secretary mentioned the pharmaceutical sector has already seen some impression within the availability of key intermediates and solvents as a result of provide chains are getting affected by the regional disaster.Agrawal mentioned all arms of the government are working to prioritise restricted LPG provide and are trying to ease the state of affairs by diversifying imports and sourcing from various suppliers.“So, as we are able to resolve that overall supply, we will try to alleviate some of the pain in every sector. The Pharma sector will be one of the priority sectors,” he mentioned.He added that the government and trade are collectively engaged on methods to make provide chains extra resilient.
Call for self-reliance in APIs, bulk medication and intermediates
At the identical occasion, Agrawal requested the pharmaceutical trade to make use of the present geopolitical uncertainty as a set off to scale back dependence on essential imported inputs and strengthen home capability.Addressing trade stakeholders in Hyderabad, he harassed “the importance of ensuring greater self-reliance by meeting 80-90 per cent (or higher) of domestic pharmaceutical requirements through indigenous production, while reducing critical import dependencies in APIs, bulk drugs, and intermediates”.He additionally emphasised the “importance of insulating import supply chains in a geopolitically fragmented world, where availability may be important”.Agrawal referred to as for a broader strategic repositioning of India as a worldwide hub for high quality, inexpensive prescribed drugs, saying that high quality would stay the decisive consider healthcare. He urged the sector to construct a stronger high quality ecosystem to boost world belief and align with rising areas corresponding to biologics and biosimilars.He additionally inspired the trade to shift from a volume-driven to a value-driven mannequin, with higher concentrate on innovation and new patents, whereas sustaining India’s power in generics.
Exports stay on optimistic path regardless of uncertainty
Despite the geopolitical overhang, Agrawal mentioned India’s exports within the final monetary 12 months have been anticipated to stay on a optimistic trajectory.The broader pharmaceutical export image stays resilient. India’s pharma exports stood at $30.47 billion in 2024-25, up 9.4 per cent over the earlier 12 months.During April–February 2025-26, pharma exports reached $28.29 billion, registering development of over 5 per cent in contrast with the corresponding interval of the earlier 12 months.India stays the third-largest producer of prescribed drugs globally by quantity and 14th by worth, underscoring each the sector’s scale and the stakes concerned in insulating it from exterior shocks.